Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 5:48 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 36 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Gabapentin Pill Clear all
Completed Not applicable Interventional Accepts healthy volunteers Results available

Oral Gabapentin Versus Placebo for Treatment of Postoperative Pain Following Photorefractive Keratectomy

NCT00793910
View directory record Official record
Conditions
Postoperative Pain
Interventions
Gabapentin, placebo
Drug
Lead sponsor
Walter Reed Army Medical Center
Federal
Eligibility
21 Years and older
Enrollment
106 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jul 15, 2014 · Synced Sep 2, 2026, 5:48 PM EDT
Completed Phase 3 Interventional Results available

Breeze3:Study of Gabapentin Extended Release in the Treatment of Vasomotor Symptoms(Hot Flashes)in Postmenopausal Women

NCT01080300
View directory record Official record
Conditions
Hot Flashes
Interventions
Gabapentin Extended Release, Placebo
Drug
Lead sponsor
Depomed
Industry
Eligibility
18 Years to 70 Years · Female only
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
66
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 63 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2020 · Synced Sep 2, 2026, 5:48 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Gabapentin in Patients at Clinical Risk for Psychosis

NCT02557945
View directory record Official record
Conditions
Clinical High Risk for Psychosis
Interventions
Gabapentin, Placebo
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 30 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 2, 2022 · Synced Sep 2, 2026, 5:48 PM EDT
Terminated Phase 4 Interventional Results available

Efficacy of Gralise® for Chronic Pelvic Pain

NCT01678911
View directory record Official record
Conditions
Irritable Bowel Syndrome, Ulcerative Colitis, Interstitial Cystitis, Prostatitis, Pelvic Pain
Interventions
Gralise
Drug
Lead sponsor
Shirley Ryan AbilityLab
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 28, 2015 · Synced Sep 2, 2026, 5:48 PM EDT
Completed Phase 2 Interventional

Acupuncture and Gabapentin for Hot Flashes Among Breast Cancer Survivors

NCT01005108
View directory record Official record
Conditions
Hot Flashes
Interventions
Gabapentin
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 14, 2020 · Synced Sep 2, 2026, 5:48 PM EDT
Completed Not applicable Interventional Results available

The Effect of Neurontin on Pain Management in the Acutely Burned Patient

NCT01265056
View directory record Official record
Conditions
Pain, Burn Injury
Interventions
Gabapentin, Placebo
Drug
Lead sponsor
Lucy A Wibbenmeyer
Other
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Jan 22, 2018 · Synced Sep 2, 2026, 5:48 PM EDT
Completed Phase 1 Interventional

Drug Discrimination in Methadone-Maintained Humans Study 1

NCT00593463
View directory record Official record
Conditions
Drug Dependence
Interventions
Cycloserine, Diltiazem, Gabapentin, Isradipine, Naloxone, Nifedipine, Placebo, Saline, Verapamil
Drug · Device
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Mar 10, 2011 · Synced Sep 2, 2026, 5:48 PM EDT
Completed Not applicable Interventional

Pre-Emptive Analgesia in Ano-Rectal Surgery

NCT02402543
View directory record Official record
Conditions
Hemorrhoids, Fissure in Ano, Rectal Fistula, Anal Condyloma
Interventions
Gabapentin, Ketamine, Acetaminophen, Dexamethasone, Placebo
Drug
Lead sponsor
University of Vermont
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
2
States / cities
Burlington, Vermont • Colchester, Vermont
Source: ClinicalTrials.gov public record
Updated Jan 15, 2018 · Synced Sep 2, 2026, 5:48 PM EDT
Completed Phase 3 Interventional Results available

Study of Gabapentin Extended Release (G-ER)in the Treatment of Vasomotor (Hot Flashes/Hot Flushes) Symptoms in Postmenopausal Women.

NCT00777023
View directory record Official record
Conditions
Hot Flashes
Interventions
Gabapentin Extended-Release (G-ER) 1200 mg, Gabapentin Extended-Release (G-ER) 1800 mg, Placebo
Drug
Lead sponsor
Depomed
Industry
Eligibility
18 Years to 70 Years · Female only
Enrollment
565 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
45
States / cities
Birmingham, Alabama • Chandler, Arizona • Scottsdale, Arizona + 40 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2012 · Synced Sep 2, 2026, 5:48 PM EDT
Completed Phase 3 Interventional Results available

Study of Gabapentin Extended Release (G-ER) in the Treatment of Vasomotor (Hot Flashes/Hot Flushes) Symptoms in Postmenopausal Women

NCT00755417
View directory record Official record
Conditions
Hot Flashes
Interventions
Gabapentin Extended-Release (G-ER) 1200 mg, Gabapentin Extended-Release (G-ER) 1800 mg, Placebo
Drug
Lead sponsor
Depomed
Industry
Eligibility
18 Years to 70 Years · Female only
Enrollment
541 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
45
States / cities
Birmingham, Alabama • Montgomery, Alabama • Tempe, Arizona + 42 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2012 · Synced Sep 2, 2026, 5:48 PM EDT
Terminated Not applicable Interventional Results available

Treatment of Complex Regional Pain Syndrome With Once Daily Gastric-Retentive Gabapentin (Gralise)

NCT01623271
View directory record Official record
Conditions
Complex Regional Pain Syndrome I (CRPS I)
Interventions
Gabapentin
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 80 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 22, 2020 · Synced Sep 2, 2026, 5:48 PM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Efficacy of Preoperative Administration of Gabapentin in 3rd Molar Dental Extraction.

NCT04860141
View directory record Official record
Conditions
Dental Pain and Sensation Disorder, Pain, Postoperative
Interventions
Gabapentin 600mg, Placebo
Drug
Lead sponsor
Loma Linda University
Other
Eligibility
18 Years to 59 Years
Enrollment
98 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Feb 3, 2026 · Synced Sep 2, 2026, 5:48 PM EDT
Enrolling by invitation Phase 4 Interventional Accepts healthy volunteers

Reducing Opioid Use After Upper Extremity Surgery: Testing Lower Prescriptions and Pill Quantity

NCT07750639
View directory record Official record
Conditions
Opioid Abuse (Disorder), Opioid Analgesia, Opioid Analgesic Adverse Reaction, Opioid Consumption
Interventions
Naproxen, Acetaminophen, oxycodone, Gabapentin
Drug
Lead sponsor
AdventHealth
Other
Eligibility
18 Years and older
Enrollment
260 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Sep 2, 2026, 5:48 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Pharmacotherapy and Mechanisms of Sleep Disturbance in Alcohol Dependence

NCT01014533
View directory record Official record
Conditions
Alcohol Dependence, Insomnia
Interventions
Placebo dispensed to subject., Gabapentin dispensed to subject.
Drug
Lead sponsor
Dr. Kirk Brower
Other
Eligibility
18 Years to 65 Years
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2011
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 5, 2017 · Synced Sep 2, 2026, 5:48 PM EDT
Recruiting Phase 3 Interventional

Emergency Department-Initiated Medications for Alcohol Use Disorder

NCT05827159
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
Naltrexone Pill, Naltrexone Injection, Brief Negotiation Interview, Gabapentin Pill
Drug · Behavioral
Lead sponsor
Yale University
Other
Eligibility
18 Years to 80 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Sep 2, 2026, 5:48 PM EDT
Terminated Phase 4 Interventional Results available

Three Way Interaction Between Gabapentin, Duloxetine, and Donepezil in Patients With Diabetic Neuropathy

NCT00619983
View directory record Official record
Conditions
Diabetic Neuropathic Pain, Chronic Low Back Pain
Interventions
donepezil, duloxetine, donepezil 2.5 mg and duloxetine 30mg, placebo, gabapentin
Drug
Lead sponsor
Wake Forest University
Other
Eligibility
18 Years to 80 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
2
States / cities
Winston-Salem, North Carolina • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 10, 2018 · Synced Sep 2, 2026, 5:48 PM EDT
Completed Phase 4 Interventional Results available

ACL Repair and Multimodal Analgesia

NCT01868425
View directory record Official record
Conditions
Pain
Interventions
multimodal:acetaminophen, gabapentin, ketamine, bupivacaine, placebo pills and injectables
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 55 Years
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 29, 2020 · Synced Sep 2, 2026, 5:48 PM EDT
Terminated Phase 4 Interventional Results available

Predicting, Understanding and Speeding Recovery After TKA

NCT02685735
View directory record Official record
Conditions
Pain, Total Knee Replacement, Total Hip Replacement
Interventions
Gabapentin, Placebo
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 70 Years
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 14, 2025 · Synced Sep 2, 2026, 5:48 PM EDT
Withdrawn Phase 4 Interventional

Oral Clonidine & Gabapentin: Improving Recovery and Pain Management After Outpatient With Major Orthopedic Surgery

NCT01112878
View directory record Official record
Conditions
Shoulder Arthroscopy, Knee Arthroscopy
Interventions
Sugar pill, Gabapentin, Clonidine
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 13, 2015 · Synced Sep 2, 2026, 5:48 PM EDT
Completed Phase 2 Interventional

Gabapentin and Tizanidine for Insomnia in Chronic Pain

NCT04429347
View directory record Official record
Conditions
Insomnia Due to Medical Condition, Chronic Pain
Interventions
Gabapentin, Placebo, Tizanidine
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 65 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jan 2, 2025 · Synced Sep 2, 2026, 5:48 PM EDT
Completed Phase 2 Interventional Results available

Gabapentin as an Adjunct to Perioperative Pain Management Regimens for Uterine Aspiration

NCT02725710
View directory record Official record
Conditions
Other Abortion, Spontaneous Abortion
Interventions
Gabapentin, Placebo
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older · Female only
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 1, 2019 · Synced Sep 2, 2026, 5:48 PM EDT
Completed Phase 2 Interventional

Study of Gabapentin Extended Release (G-ER) in the Treatment of Vasomotor (Hot Flashes/Hot Flushes) Symptoms in Postmenopausal Women

NCT00511953
View directory record Official record
Conditions
Hot Flashes
Interventions
Gabapentin Extended Release tablets, Gabapentin
Drug
Lead sponsor
Depomed
Industry
Eligibility
18 Years and older · Female only
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
8
States / cities
Burbank, California • DeLand, Florida • Port Orange, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2011 · Synced Sep 2, 2026, 5:48 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Gabapentin in Postherpetic Neuralgia

NCT00636636
View directory record Official record
Conditions
Neuralgia,Postherpetic
Interventions
Gabapentin Extended Release tablets, Placebo
Drug
Lead sponsor
Depomed
Industry
Eligibility
18 Years and older
Enrollment
452 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
36
States / cities
Birmingham, Alabama • Tuscaloosa, Alabama • Phoenix, Arizona + 33 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2012 · Synced Sep 2, 2026, 5:48 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Gabapentin for Smoking Cessation

NCT00578552
View directory record Official record
Conditions
Cigarette Smoking, Tobacco Use
Interventions
Placebo, Gabapentin - 1800 mg/day, Gabapentin - 2700 mg/day
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 18, 2011 · Synced Sep 2, 2026, 5:48 PM EDT